-+ 0.00%
-+ 0.00%
-+ 0.00%

EQT Life Sciences participates in Vaderis Therapeutics' USD 152 million Series B financing

Barchart·08/11/2026 06:54:00
Listen to the news

STOCKHOLM, Aug. 11, 2026 /PRNewswire/ --

EQT Life Sciences is pleased to announce its participation in Vaderis Therapeutics' USD 152 million Series B financing through one of its managed funds, with a USD 17.5 million investment. The financing was co-led by Life Sciences at Goldman Sachs Alternatives and TCGX, with participation from Omega Funds, Perceptive Advisors, Kalehua Capital and existing investors Medicxi and Droia. The proceeds will support Vaderis with capital needs through potential regulatory approval of engasertib, the company's lead program for hereditary hemorrhagic telangiectasia (HHT).

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.